About Breakpoint Therapeutics

Breakpoint Therapeutics, founded in 2019, is a biotechnology company focused on discovering and developing novel anti-cancer drugs. By targeting the DNA damage response in cancer cells, the company aims to advance first-in-class oncology therapies into clinical development that interfere with DNA repair mechanisms and replication stress tolerance pathways. Breakpoint Therapeutics’ mission is to develop innovative treatments that complement PARP inhibitors and address therapy-resistant cancers, ultimately improving outcomes for patients with difficult-to-treat malignancies.